Seroatlas · Human Serome Atlas

CBR3

Carbonyl reductase [NADPH] 3

Also known as: CBR3_HUMAN, SDR21C2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O75828
Gene: CBR3
Ensembl: ENSG00000159231
Chromosome: 21
Canonical length: 277 aa
Protein class: Enzymes, Metabolic proteins, Predicted intracellular proteins
Subcellular location: Nucleoplasm,Cytosol

OverviewNCBI Gene

Carbonyl reductase 3 catalyzes the reduction of a large number of biologically and pharmacologically active carbonyl compounds to their corresponding alcohols. The enzyme is classified as a monomeric NADPH-dependent oxidoreductase. CBR3 contains three exons spanning 11.2 kilobases and is closely linked to another carbonyl reductase gene - CBR1. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

277 residues, UniProt reviewed canonical sequence.

>O75828|CBR3
     1  MSSCSRVALV TGANRGIGLA IARELCRQFS GDVVLTARDV ARGQAAVQQL QAEGLSPRFH
    61  QLDIDDLQSI RALRDFLRKE YGGLNVLVNN AAVAFKSDDP MPFDIKAEMT LKTNFFATRN
   121  MCNELLPIMK PHGRVVNISS LQCLRAFENC SEDLQERFHS ETLTEGDLVD LMKKFVEDTK
   181  NEVHEREGWP NSPYGVSKLG VTVLSRILAR RLDEKRKADR ILVNACCPGP VKTDMDGKDS
   241  IRTVEEGAET PVYLALLPPD ATEPQGQLVH DKVVQNW

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CBR3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.23
Highest tissue expression: 65 nTPM

Expression across tissuesHPA

Tissue

esophagus: 65 nTPM
salivary gland: 46 nTPM
basal ganglia: 21 nTPM
skin: 21 nTPM
adipose tissue: 19 nTPM
vagina: 19 nTPM

Single-cell type

esophageal suprabasal cells: 376 nCPM
esophageal apical cells: 286 nCPM
suprabasal keratinocytes: 227 nCPM
esophageal basal cells: 206 nCPM
salivary ionocytes: 178 nCPM
salivary acinar cells: 154 nCPM

Immune cell

naive CD4 T-cell: 34 nTPM
memory CD4 T-cell: 25 nTPM
naive B-cell: 24 nTPM
memory B-cell: 24 nTPM
naive CD8 T-cell: 24 nTPM
NK-cell: 12 nTPM

Brain region

basal ganglia: 13 nTPM
cerebellum: 11 nTPM
cerebral cortex: 9.8 nTPM
medulla oblongata: 8.9 nTPM
amygdala: 8.5 nTPM
hypothalamus: 7.8 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.8
gnomAD pLI: 0
gnomAD missense Z: -0.03
DepMap mean gene effect: 0.01
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of CBR3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

CBR1

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CBR3 as an antibody target. Whether an autoantibody or antibody against CBR3 could matter depends on whether native CBR3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CBR3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label CBR3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...